Alvaro Herrera Pérez/LinkedIn
Jun 13, 2026, 16:21
Alvaro Herrera Pérez: Connecting Science and Care at EHA 2026
Alvaro Herrera Pérez, European MSL Lead at Agios Pharmaceuticals, shared a post on LinkedIn:
”Attending EHA 2026 at Stockholm.
Different country, same mission: collaborating with colleagues across Europe and the United States (Clinical Development and Medical Affairs) united by a common purpose: Improving outcomes for patients.
Scientific exchange, innovation, and teamwork continue to drive us forward, always with the patient at the center of everything we do.”
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 13, 2026, 16:07Isabelle Mahé: Connecting Expertise in Antithrombotic Care at ISTH 2026
-
Jun 13, 2026, 16:02Tarun Aurora։ Towards Better Risk Stratification in Sickle Cell Disease
-
Jun 13, 2026, 15:59Irene Cuppari: Whole Blood and Component Therapy in Traumatic Hemorrhage
-
Jun 13, 2026, 15:39Ritu Verma: Recognizing Deep Vein Thrombosis Before Complications Arise
-
Jun 13, 2026, 15:09Akshat Jain: Does Mitapivat Translate to Clinical Benefit in SCD?
-
Jun 13, 2026, 14:58Olga Benítez Hidalgo: New Evidence on Marstacimab in Hemophilia Care
-
Jun 13, 2026, 14:52Sophie Georgin-Lavialle: First ERN-RITA Recommendations on USAID
-
Jun 13, 2026, 14:48Andrew Jackson: Personalized Approaches to Catheter-Related Thrombosis Prevention
-
Jun 13, 2026, 14:45Ghazaleh Bankefors: Reconnecting Across Borders and Decades at EHA 2026